SynthesisBMC immunology2025
Efficacy and safety of toripalimab in the treatment of nasopharyngeal carcinoma: a meta-analysis of single-arm trials.
Synthesis in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasopharyngeal carcinoma (NPC) is common in East Asia, and treatment options are limited. Toripalimab, a PD-1 inhibitor, has potential in NPC therapy.
objectiveThis meta-analysis aimed to evaluate the efficacy and safety of toripalimab in the treatment of NPC.
methodsA systematic search of PubMed, Embase, the Cochrane Library and Web of Science was conducted to identify studies assessing toripalimab in NPC. The search time ranged from the establishment of the database to January 10, 2025. R4.4.1 software was used for data analysis.
resultsNine papers (with a total of 801 patients) were included, of which 2 were randomized controlled studies and 7 were single-arm studies. Meta-analysis results suggest that after treatment with toripalimab, the ORR of NPC was 77% (95% CI 55%-90%)], DCR was 93% (95% CI 81%-100%), 1-year OS was 81% (95% CI 43%-100%), 2-year OS was 68% (95% CI 0%-100%), 3-year OS was 75% (95% CI 42%-97%), 1-year PFS was 81% (95% CI 62%-91%), 2-year PFS was 56% (95% CI 26%- 82%), 3-year PFS was 25% (95% CI 7%-60%), the rate of adverse events was 98% (95% CI: 90%-100%), and the rate of grade ≥ 3 was 76% (95% CI: 52%-94%).
conclusionsThese results suggest that toripalimab has better efficacy in the treatment of NPC, especially in terms of disease control and survival. However, it was also accompanied by a high incidence of adverse events, especially grade ≥ 3 adverse events. Because there was no control group in this study, caution is needed when interpreting the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.